Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

This communication relates solely to the investment activities of the mentioned Special Situations Investment Funds, which form part of the GAM Alternatives business. Activist engagement is undertaken by the funds' investment managers in pursuit of the funds' stated investment objective. It should not be interpreted as a statement of corporate policy or opinion by GAM Investments. Activist investors Albert Saporta and Randel Freeman cite significant undervaluation, c. 85% share price decline from peak, and ...

Infrastructure Damage Is a Bigger Problem Than Shipping Delays Iran isn't just blocking the Strait. It's hitting export terminals and processing plants. That's a different problem. Shipping delays end when the route reopens. Damaged infrastructure takes time to fix and that means supply stays tight longer. Traders are starting to price that in and it's more bullish than a temporary blockage. The trend is up according to the swing chart, but mostly because we are on the strong side of the 52-week moving aver ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Navan, Inc. during its October 2025 IPO about the April 24, 2026 deadline to become a lead plaintiff in a class action lawsuit due to alleged misleading information in the Offering Documents [1]. Group 1: Class Action Details - Investors who purchased Navan common stock may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by April 24, 2026, to serve as lead plaintiff, representing other class members in the litigation [3]. - The lawsuit claims that the Offering Documents for Navan's IPO were false and misleading, particularly regarding increased "sales and marketing" expenses at the time of the offering, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - The German food-delivery company is selling Foodpanda for $600 million in cash as part of a strategic review [1] Group 1 - The sale of Foodpanda is a strategic decision aimed at optimizing the company's portfolio [1] - The transaction is valued at $600 million, indicating a significant move in the company's operational strategy [1]

There's a lot going on right now, and I've got way more questions than answers. Here are a few that seem important: t of the last an 1 2 and t r t 型 th 4 - r r r Parti le and the latest e r 4 % t Pr t t lan hallojulie/iStock via Getty Images Is this stock market correction the beginning of a bear market? Obviously, no one ...

Goldman Sachs expects ECB rate hikes in April and June as inflation concerns mount | Reuters Skip to main content Reporting by Kanchana Chakravarty in Bengaluru; Editing by Rashmi Aich Our Standards: The Thomson Reuters Trust Principles., opens new tab Purchase Licensing Rights Business Siemens CEO says customers holding back on investments due to Iran war Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv EU flags flutter in front of European Central Bank (ECB) h ...

Group 1 - Oil prices experienced a significant increase, indicating a potential shift in market dynamics [1] - Asian equities and government bonds saw a decline across the board, reflecting investor sentiment and market reactions to rising oil prices [1]

Core Insights - Just - Evotec Biologics has entered a project agreement with BARDA to optimize biomanufacturing of antibodies against Ebola and related viruses, enhancing U.S. government response capabilities to hemorrhagic fever outbreaks [1][2] Group 1: Project Agreement Details - The multi-year program is valued at up to $10 million if all options are activated, aimed at developing cost-effective medical countermeasures for filovirus diseases [2] - The agreement includes a base period and two option periods, addressing the lack of approved treatments for Sudan virus infections [2] Group 2: Technological Approach - Just - Evotec Biologics will utilize its advanced biomanufacturing platform for molecular optimization, cell line development, and manufacturing process development for two antibodies identified in Ebola survivors [3] - The focus is on delivering high-yield, scalable, and cost-efficient production processes to support rapid deployment in public health emergencies [3] Group 3: Organizational Background - Just - Evotec Biologics is a subsidiary of Evotec SE, leveraging AI/ML technologies and advanced manufacturing strategies to accelerate biotherapeutics from discovery to commercial launch [7] - Evotec SE is a life science company that integrates breakthrough science with AI-driven innovation, focusing on drug discovery and development across various therapeutic areas [8]

Core Viewpoint - Finnair has decided to renew its European fleet by ordering 18 E195-E2 narrow-body aircraft from Embraer, moving away from Airbus as its current provider [1][2]. Group 1: Fleet Renewal and Aircraft Details - The order includes options for 16 additional E195-E2 aircraft and purchase rights for a further 12 [3]. - Finnair plans to acquire up to 12 used Airbus A320 or A321 aircraft from the secondary market [2]. - The E195-E2 is noted for being highly versatile and one of the quietest aircraft available [2]. Group 2: Environmental Impact - The new aircraft will reduce CO emissions by 30 percent per passenger carried, supporting Finnair's climate objectives [3]. Group 3: Market Context and Strategic Moves - Finnair's decision is a setback for Airbus, as Embraer's E2 series outsold the Airbus A220 by a ratio of three to one last year [2]. - The airline has been navigating challenges from the COVID-19 pandemic and airspace closures due to geopolitical tensions since 2022 [4]. - Finnair had previously indicated an urgent need to replace 15 older models from its narrow-body fleet of 29 Airbus planes [5].